Sep 26, 2022
Immutep to Participate in Two Upcoming Investor Conferences
Sep 22, 2022
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Sep 13, 2022
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Sep 12, 2022
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Sep 05, 2022
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
